Abstract
HIV resistance to approved therapeutics is an increasing concern necessitating the need for development of new therapeutic approaches. Elusys's novel Heteropolymer (HP) technology consists of two monoclonal antibodies that are chemically cross-linked: one specific for complement receptor type 1 (CR1, CD35) on red blood cells (RBCs) and the other recognizing the target pathogen. Previous studies with multiple families of viruses have demonstrated that administration of HPs leads to rapid immobilization of virus to RBCs followed by delivery to the Kupffer cells of the liver where the viruses were destroyed. Two different HIV HPs with distinct gp120 binding specificities were generated and shown to simultaneously bind to transgenic mouse (TgN) RBCs (expressing human CR1) and gp120 in vitro by FACS analysis. Both HIV HPs were able to reduce the circulation in plasma of inactivated HIV more rapidly than the corresponding HIV Mabs in the TgN mouse. Both HIV HPs neutralized HIV strains SF162 and NL4-3 while only HIV HP 2 was able to neutralize SHIV89.6P. These results support Elusys continuing efforts and testing of HIV HP as a new therapeutic approach.
Highlights
2006 International Meeting of The Institute of Human Virology Meeting abstracts
HIV resistance to approved therapeutics is an increasing concern necessitating the need for development of new therapeutic approaches
Elusys's novel Heteropolymer (HP) technology consists of two monoclonal antibodies that are chemically cross-linked: one specific for complement receptor type 1 (CR1, CD35) on red blood cells (RBCs) and the other recognizing the target pathogen
Summary
A novel dual antibody conjugate (Heteropolymer) reduces circulating HIV in a mouse model SE Pincus*1, SM Jones1, TA Bradley1, J Dunne1, Q Wang1, WJ Honnen2, R Kunert3 and A Pinter2 Address: 1Elusys Therapeutics, Pine Brook, NJ 07058, USA, 2Public Health Research Institute, Newark, NJ 07103, USA and 3Institute of Applied Microbiology, Vienna, Austria
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.